Aspergillus fumigatus is the second clinically important fungal pathogen, causes invasive aspergillosis and accounts for about 65% of all invasive fungal infections in humans. The mortality associated with A. fumigatus infection exceeds 50% despite treatment with current standard of care antifungal drugs, which is due to limited drug options, low efficiency and drug resistance, and new drugs are urgently needed. However, a major barrier to develop novel therapies is the lack of improved understanding of fungal pathogen. The transcriptomic analysis of Aspergillus fumigatus can help to predict regulatory pathways in this fungus based on RNA-Seq.